Quark Pharmaceuticals

Type: Company

Name: Quark Pharmaceuticals

First reported May 13 2013 - Updated May 13 2013 - 2 reports

Antisense Therapeutics Ltd

Just Published: Global Diabetic Retinopathy Market 2012-2016 - MarketResearchReports.Biz

TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of 35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic ... [Published MyNewsDesk - May 13 2013]

Entities: Market, Novagali Pharma SA, Excaliard Pharmaceuticals Inc, Antisense Therapeutics Ltd

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2013

Research and Markets has announced the addition of the "" report to their offering. '', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic ... [Published Individual.com - Apr 16 2013]

Entities: Chronic Renal Failure, Chronic Kidney Disease, Therapeutics, Sorbent Therapeutics, Quark Pharmaceuticals

First reported Apr 12 2013 - Updated Apr 12 2013 - 1 reports

Lung Transplantation - Pipeline Review, H1 2013

Research and Markets has announced the addition of the "" report to their offering. '', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with ... [Published Individual.com - Apr 12 2013]

Entities: Lung Transplantation, Drugs, Therapeutics, Quark Pharmaceuticals, PROTEO INC

Quotes

Research and Markets has announced the addition of the "" report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development - Alexion Pharmaceuticals Inc. - Amgen Inc. - Angion Biomedica Corp. - Ardelyx, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bolder Biotechnology, Inc. - Catabasis Pharmaceuticals, Inc. - Cellmid Ltd - Concert Pharmaceuticals Inc. - CorMedix Inc. - Dynavax Technologies Corporation - Eli Lilly and Company - Evotec Aktiengesellschaft - FibroGen Inc. - Hawthorn Pharmaceuticals Inc. - InVasc Therapeutics, Inc. - Kureha Corporation - La Jolla Pharmaceutical Company - Nile Therapeutics Inc. - Pieris AG - Promedior Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals Inc. - Sorbent Therapeutics, Inc. - Stelic Institute & Co. - Thrasos, Inc. - Vicore Pharma AB - Vitae Pharmaceuticals Inc. For more information visit Research and Markets CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Pharmaceuticals (http://www.researchandmarkets.com/categories.asp?cat_id=16&campaign_id=zp8s48)"

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2013 [Published Individual.com - Apr 16 2013]

Research and Markets has announced the addition of the "" report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Lung Transplantation Therapeutics Development - Quark Pharmaceuticals, Inc. - Vectura Group plc - Proteo Inc. - APT Pharmaceuticals, Inc. Drug Profiles - Elafin - Drug Profile - cyclosporine - Drug Profile - Respiratory And Inflammatory Diseases Program - Drug Profile - VR-909 - Drug Profile - Autologous Mesenchymal Stem Cells Transplantation - Drug Profile For more information visit Research and Markets About Research and Markets Research and Markets is the world's leading source for international marketmarket research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Immune Disorders (http://www.researchandmarkets.com/categories.asp?cat_id=120&campaign_id=p575f6)"

Lung Transplantation - Pipeline Review, H1 2013 [Published Individual.com - Apr 12 2013]